Escherichia coli from urine samples of pregnant women as an indicator for antimicrobial resistance in the community: a field study from rural Burkina Faso

Table 1 Total numbers of samples with numbers of significant growth for 5741 healthy pregnant women, matched by parity and trimester of pregnancy

Patients for whom complete data were available	Total		Trimester 1		Trimester 2		Trimester 3
n = 5741	n = 5741		n = 227		n = 1889		n = 3625
n = 5741	nr. Cases	% growth	nr. Cases	% growth	nr. Cases	% growth	nr. Cases	% growth
Gestation
Nullipara (percentage significant growth)	7	0%	1	0%	1	0%	5	0%
Primipara (percentage significant growth)	1367	3.9%	65	4.6%	538	3.9%	784	3.7%
Multipara (percentage significant growth)	2493	3.0%	99	4.0%	832	3.5%	1562	2.7%
Grand multipara (percentage significant growth)	1874	2.4%	62	0%	518	2.9%	1294	2.3%
Age distribution (years [IQR])	25 (20–30)		24 (20–30)		24 (19–30)		26 (21–30)
Dipstick results
Nitrite* (n [%])	68 (1.2%)	7 (3.1%)	29 (1.5%)				32 (0.9%)
Leukocytes* (n [%])	1055 (18.4%)	44 (19.4%)	318 (16.8%)				717 (19.1%)
Dipslide results**
< 10⁴ CFU/ml	2865 (49.9%)		125 (55.1%)		905 (47.9%)		1835 (50.6%)
≥ 10⁴ CFU/ml	643 (11.2%)		18 (7.9%)		184 (9.7%)		441 (12.1%)
Clinically significant growth	173 (3.4%)		7 (3.1%)		65 (3.4%)		101 (2.8%)
Asymptomatic bacteriuria	97 (1.7%)		4 (1.8%)		37 (2.0%)		56 (1.5%)

Significant growth is defined as growth of Enterobacterales in counts of ≥ 10⁴ CFU/ml. Parity was defined as follows: nullipara = never give birth, primipara = given birth once, multipara = parity ≥ 2, grand multipara = parity ≥ 5 [18]
Data differ slightly from those in Fig. 2 where data are presented for all samples
Clinically significant growth is defined as growth with an Enterobacterales species in counts of ≥ 10⁴ CFU/ml
Asymptomatic bacteriuria is defined as clinically significant growth with counts of ≥ 10⁵ CFU/ml

ISSN: 2047-2994